Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Vemurafenib

fcf06540-7e7a-5e20-9306-cb18e8c07120 · FDA Approved · targets BRAF

Vemurafenib

MeasuredReference

Vemurafenib targets LCK, KHS_MAP4K5, MAP2K2. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

LCKKHS_MAP4K5MAP2K2PTK6ARAF

Top hallmarks

  • tumor promoting inflammation5.3k
  • proliferation4.4k
  • evading apoptosis4.3k

Top pathways disrupted

  • pi3k akt mtor signaling9.0k
  • apical junction8.7k
  • allograft rejection8.3k

Resistance landscape — Vemurafenib

MeasuredReference

No variant annotations found on Vemurafenib's top targets.

No variant annotations on Vemurafenib's top targets.
Open in new tab